AMRI Completes Acquisition of Euticals
ALBANY, N.Y., July 11, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Prime European Therapeuticals S.p.A., also known as "Euticals", a privately-held company headquartered inLodi, Italy, specializing in custom synthesis and the manufacture of ac...
AMRI to Acquire Euticals in a Strategic Transaction That Expands its API Development and Manufacturing Business
ALBANY, N.Y., May 5, 2016 /PRNewswire/ -- * Enters definitive agreement to acquire Euticals for $358 million in stock, cash and a seller note * Positions AMRI as one of the largest independent developers and suppliers of API to the pharmaceutical industry * Significantly expands AMRI's pre...
AMRI and PerkinElmer Announce Drug Discovery Collaboration as part of the Buffalo Medical Innovation and Commercialization Hub
BUFFALO, N.Y., June 17, 2015 /PRNewswire/ -- As further evidence of Governor Andrew M. Cuomo's successful establishment of a dynamic and growing bio-pharma sector inBuffalo, New York, Albany Molecular Research Inc. (NASDAQ: AMRI) and PerkinElmer, Inc. today announced the formation of a strategic ...
AMRI to Close Holywell, U.K. API Manufacturing Facility
ALBANY, N.Y., April 3, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives. The Holywell site provides chemical development services and small- and large scale-manufacturin...
AMRI Completes Acquisition of Oso Biopharmaceuticals Manufacturing
ALBANY, N.Y., July 2, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners, LLC. The transaction is consistent with AMRI's strategy to be the preeminent suppli...
